Servier engages BioInvent for cancer antibody
Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library for antibodies specific to the undisclosed target. For its services, BioInvent will receive a licensing fee, research support and potential milestone payments of more than €11m, as well as royalty on future sales of the product."Oncology is a prioritised area for BioInvent", said Svein Mathisen, President and CEO of BioInvent. As part of the cooperation, Servier will have access to BioInvent's in-house pre-clinical capacities in selecting an antibody candidate for development. “The Bioinvent n-CoDeR library will be used in combination with a functional assay set up at Servier to select antibody candidates", said Stéphane Depil, in charge of Oncology R&D at Servier. "This is expected to enable us to develop one of the first monoclonal antibodies targeting tumour cell metabolism, an approach anticipated to have major therapeutic potential.” Servier is used to these kinds of cooperations. In 2011 it started working together with Belgian biotech Galapagos and US-Intercept Pharmaceuticals.